2C-C

Use and effects

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists 2C-C's dose range as 20 to 40mg orally and its duration as 4 to 8hours. Its onset is described as delayed compared to 2C-B and as being 1.5 to 2hours. In addition to oral administration, a single report of 20mg by intravenous injection was described as overwhelming, with effects peaking after 5minutes and lasting perhaps 15minutes. The effects of 2C-C have been reported to include psychedelic visuals, sensual enhancement, stimulation, sedation, and relaxation, among others. Its stimulating effects are said to be less than those of 2C-B and it is said to be sedating in some ways.

Interactions

2C drugs like 2C-C are known to be metabolized by the monoamine oxidase (MAO) enzymes MAO-A and MAO-B. Monoamine oxidase inhibitors (MAOIs) such as phenelzine, tranylcypromine, moclobemide, and selegiline may potentiate the effects of 2C drugs like 2C-C. This may result in overdose and serious toxicity.

Pharmacology

Pharmacodynamics

2C-C acts as an agonist of the serotonin 5-HT2 receptors. It also binds to the serotonin 5-HT1A receptor with 15-fold lower affinity than for the serotonin 5-HT2A receptor. The drug shows little or no affinity for the monoamine transporters (MATs) and shows very weak or negligible monoamine reuptake inhibition. It shows high affinity for the rat trace amine-associated receptor 1 (TAAR1), but only weak affinity for the mouse TAAR1.

In contrast to many other psychedelics, 2C-C, as well as 2C-P and certain 2C NBOMe analogues, has shown reinforcing effects in rodents. It produces dose-dependent conditioned place preference (CPP) in mice and self-administration in rats. These findings suggest that 2C-C may have misuse potential. The mechanism by which these effects are produced is unknown. However, 2C-C was found to decrease dopamine transporter (DAT) expression and to increase DAT phosphorylation in the nucleus accumbens and medial prefrontal cortex (mPFC) similarly to methamphetamine in rodents. Decreased DAT expression may result in reduced dopamine reuptake, while DAT phosphorylation is associated with dopamine reverse transport and efflux, in turn increasing extracellular dopamine levels.

2C-C has also been found to produce neurotoxicity at high doses in rodents, which appears to be mediated via neuroinflammation.

Chemistry

Synthesis

The chemical synthesis of 2C-C has been described.

Analogues

Analogues of 2C-C include 2C-B, 2C-I, DOC, and 25C-NBOMe, among others.

History

2C-C was first described in the scientific literature by Alice Cheng and Neal Castagnoli in 1984. It was described in greater detail, including its properties and effects in humans, by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).

Society and culture

Legal status

Canada

As of October 31, 2016; 2C-C is a controlled substance (Schedule III) in Canada.

China

As of October 2015 2C-C is a controlled substance in China.

Finland

Scheduled in the "government decree on psychoactive substances banned from the consumer market".

Germany

2C-C is an Anlage I controlled drug.

Sweden

Sveriges riksdags health ministry Statens folkhälsoinstitut classified 2C-C as "health hazard" under the act Lagen om förbud mot vissa hälsofarliga varor (translated Act on the Prohibition of Certain Goods Dangerous to Health) as of Mar 1, 2005, in their regulation SFS 2005:26 listed as 2,5-dimetoxi-4-klorfenetylamin (2C-C), making it illegal to sell or possess.

United States

As of July 9, 2012, in the United States 2C-C is a Schedule I substance under the Food and Drug Administration Safety and Innovation Act of 2012, making possession, distribution and manufacture illegal.

References

References

1. "2C-C".
2. (April 1984). "Synthesis and physicochemical and neurotoxicity studies of 1-(4-substituted-2,5-dihydroxyphenyl)-2-aminoethane analogues of 6-hydroxydopamine". Journal of Medicinal Chemistry.
3. (June 27, 2012). "S. 3187: Food and Drug Administration Safety and Innovation Act, Subtitle D-Synthetic Drugs". FDA.
4. (June 2013). "2C or not 2C: phenethylamine designer drug review". Journal of Medical Toxicology.
5. (January 2007). "Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series)". Biochemical Pharmacology.
6. (January 2024). "Drug-drug interactions involving classic psychedelics: A systematic review". Journal of Psychopharmacology.
7. (16 March 2025). "Kᵢ Database".
8. "BindingDB BDBM50240789 2-(4-Chloro-2,5-dimethoxy-phenyl)-ethylamine::2-(4-chloro-2,5-dimethoxyphenyl)ethylamine::CHEMBL124733".
9. (December 2015). "Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)". Neuropharmacology.
10. (March 2014). "Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function". Psychopharmacology.
11. (March 2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology.
12. (2022). "Structure-activity Relation of Halogenated 2,5-Dimethoxyamphetamines Compared to their α‑Desmethyl (2C) Analogues". The FASEB Journal.
13. (October 2020). "In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor". Archives of Toxicology.
14. (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". The Journal of Pharmacology and Experimental Therapeutics.
15. (June 2025). "Toxicodynamic insights of 2C and NBOMe drugs - Is there abuse potential?". Toxicology Reports.
16. (April 2021). "New designer phenethylamines 2C-C and 2C-P have abuse potential and induce neurotoxicity in rodents". Archives of Toxicology.
17. (2013). "Phenethylamine: von der Struktur zur Funktion". Nachtschatten-Verlag.
18. (4 May 2016). "Canada Gazette – Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)".
19. (27 September 2015). "关于印发《非药用类麻醉药品和精神药品列管办法》的通知". China Food and Drug Administration.
20. "Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista".
21. "20050026".
22. "Erowid 2C-C Vault : Legal Status".